Difference between revisions of "Etoposide (Vepesid)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 5: Line 5:
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 +
 +
==Diseases for which it is used==
 +
*[[Acute myeloid leukemia]]
 +
*[[Acute promyelocytic leukemia]]
 +
*[[Acute lymphocytic leukemia]]
 +
*[[Aggressive Non-Hodgkin lymphoma]]
 +
*[[Bone cancer]]
 +
*[[Central nervous system (CNS) cancer]]
 +
*[[Esophageal cancer]]
 +
*[[Follicular lymphoma]]
 +
*[[Hepatobiliary cancer]]
 +
*[[HIV-associated lymphoma]]
 +
*[[Hodgkin lymphoma]]
 +
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]]
 +
*[[Mantle cell lymphoma]]
 +
*[[Multiple myeloma]]
 +
*[[Neuroendocrine tumors]]
 +
*[[Non-small cell lung cancer]]
 +
*[[Ovarian cancer]]
 +
*[[Sarcoma]]
 +
*[[Small cell lung cancer]]
 +
*[[T-cell lymphoma]]
 +
*[[Testicular cancer]]
 +
*[[Thymoma]]
 +
*[[Unknown primary]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 10: Line 35:
 
*[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref>
  
 +
==History of changes in FDA indication==
 +
*11/10/1983: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]]
 
==Also known as==
 
==Also known as==
 
{| border="1" style="text-align:center;"
 
{| border="1" style="text-align:center;"
Line 116: Line 143:
 
[[Category:Irritant chemotherapy]]
 
[[Category:Irritant chemotherapy]]
 
[[Category:Topoisomerase inhibitors]]
 
[[Category:Topoisomerase inhibitors]]
 +
 
[[Category:Acute lymphocytic leukemia medications]]
 
[[Category:Acute lymphocytic leukemia medications]]
 
[[Category:Acute myeloid leukemia medications]]
 
[[Category:Acute myeloid leukemia medications]]
Line 140: Line 168:
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Transplant medications]]
 
[[Category:Transplant medications]]
 +
 +
[[Category:Drugs FDA approved in 1983]]

Revision as of 15:37, 23 October 2014

General information

Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

Synonyms
Abic Etoposide Aside Beposid Bioposide BO RUI Bristol VP-16 Celltop Citodox
Epocin Eposid Eposide Eposido Eposin Epsidox ETO Etocris
Etomedac Etonolver Etopofos Etopophos Etopos Etoposid Etoposide Abic Etoposid Ebewe
Etoposide Bigmar Etoposide BVI Etoposide Dakota Etoposide DBL Etoposide DUP Etoposide Ebewe Etoposide Eurocept Etoposide Merck
Etoposide Pfizer etoposide phosphate Etoposide Teva Etoposid Mayne Etoposido Etoposido Delta Farma Etoposido Ferrer Etoposido GI Kendr
Etoposido Servycal Etoposido Varifarm Etoposid Proreo Etoposid Teva Etopoxan Etopul Etosid Etosin
Eunades CS Euvaxon Exitop Fytop Fytosid HAI WEI LIN Labimion Lastet
Lastet S Neoplaxol Nexvep Onkoposid Optasid P&U Etoposide Percas Posid
Posidon Posyd Riboposid Sintopozid Toposar Toposide Toposin Topresid
Tosuben Vepefos Vepeside Vepesid K Vepesid S Vepesid VP-16 Vepsid Vepside
VP-16 VP-TEC VP 16213

References

  1. ↑ 1.0 1.1 Etoposide (Vepesid) package insert
  2. ↑ Etoposide (Vepesid) package insert (locally hosted backup)
  3. ↑ Etoposide (Vepesid) patient drug information (Chemocare)
  4. ↑ Etoposide (Vepesid) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Etoposide_(Vepesid)&oldid=5161"